Gulf International Bank (uk) Ltd buys $23,724,227 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Gulf International Bank (uk) Ltd scooped up 450 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 13, 2016. The investment management firm now holds a total of 235,757 shares of Celgene Corporation which is valued at $23,724,227.Celgene Corporation makes up approximately 0.39% of Gulf International Bank (uk) Ltd’s portfolio.

Other Hedge Funds, Including , Highland Capital Management boosted its stake in CELG in the latest quarter, The investment management firm added 979 additional shares and now holds a total of 59,773 shares of Celgene Corporation which is valued at $6,014,957. Celgene Corporation makes up approx 0.51% of Highland Capital Management’s portfolio.Patten Patten Inctn reduced its stake in CELG by selling 1,040 shares or 1.78% in the most recent quarter. The Hedge Fund company now holds 57,549 shares of CELG which is valued at $5,849,280. Celgene Corporation makes up approx 0.76% of Patten Patten Inctn’s portfolio.Daiwa Sb Investments Ltd. reduced its stake in CELG by selling 4,520 shares or 30.52% in the most recent quarter. The Hedge Fund company now holds 10,290 shares of CELG which is valued at $1,045,876. Celgene Corporation makes up approx 0.27% of Daiwa Sb Investments Ltd.’s portfolio.Hilton Capital Management boosted its stake in CELG in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 7,005 shares of Celgene Corporation which is valued at $730,411. Celgene Corporation makes up approx 0.19% of Hilton Capital Management’s portfolio.Telemus Capital reduced its stake in CELG by selling 816 shares or 1.73% in the most recent quarter. The Hedge Fund company now holds 46,480 shares of CELG which is valued at $4,893,879. Celgene Corporation makes up approx 0.55% of Telemus Capital’s portfolio.

Celgene Corporation closed down -2.63 points or -2.52% at $101.64 with 34,28,438 shares getting traded on Tuesday. Post opening the session at $103.6, the shares hit an intraday low of $101.021 and an intraday high of $103.881 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.